{"entity":{"id":"nct05315700","kind":"trial","name":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","aka":[],"tldr":"A phase 1/2 trial of ORIC-114 in advanced solid tumours, run by ORIC Pharmaceuticals, now recruiting.","summary":"Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration is a phase 1/2 interventional study registered as NCT05315700 by ORIC Pharmaceuticals, with 350 participants planned, started 2022-03-10 and due to reach its primary completion in 2026-09. Interventions recorded: ORIC-114 and Chemotherapy drug.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05315700","url":"https://clinicaltrials.gov/study/NCT05315700"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["oric-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05315700","phase":"1/2","setting":"An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration","sponsor":"ORIC Pharmaceuticals","participation":[{"nct":"NCT05315700","source":"https://clinicaltrials.gov/study/NCT05315700","fetchedAt":"2026-10-07T16:53:39.725Z","studySha256":"7f10057e0575016319adc7b2002d03bf8845bab7b55f9dd930d23191c6810841","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-04","leadSponsor":"ORIC Pharmaceuticals","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":350,"enrolmentType":"ESTIMATED","siteCount":42,"recruitingSiteCount":42,"countries":["Australia","Canada","Hong Kong","Malaysia","Poland","South Korea","Spain","Taiwan","United Kingdom","United States"]}],"started":"2022-03-10","startedType":"actual","enrolled":350,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05315700/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"oric-pharmaceuticals","kind":"company","name":"ORIC Pharmaceuticals","route":"/companies/oric-pharmaceuticals/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}